Core Viewpoint - The stock price of Weikang Pharmaceutical has experienced significant fluctuations, with a year-to-date increase of 75.45% and a recent decline of 2.13% on November 6, 2023 [1][2]. Financial Performance - For the period from January to September 2025, Weikang Pharmaceutical reported a revenue of 151 million yuan, representing a year-on-year decrease of 59.20%. The net profit attributable to the parent company was -124 million yuan, a decline of 380.87% compared to the previous year [2]. - Cumulative cash distribution since the A-share listing amounts to 179 million yuan, with 55.4 million yuan distributed over the past three years [3]. Stock Market Activity - The stock has seen a 14.21% increase over the last five trading days and a 17.59% increase over the last 20 days [2]. - As of September 30, 2023, the number of shareholders increased to 10,600, up by 7.09%, while the average circulating shares per person decreased by 6.62% to 13,605 shares [2]. Company Overview - Weikang Pharmaceutical, established on March 31, 2000, and listed on August 24, 2020, is located in Lishui Economic Development Zone, Zhejiang Province. The company focuses on the research, production, and sales of modern Chinese and Western medicines, with 97.16% of its revenue coming from traditional and Western medicine products [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the Chinese medicine sub-sector, and is associated with concepts such as small-cap stocks, private hospitals, anti-influenza, and pharmaceutical e-commerce [2]. Trading Activity - On November 6, 2023, Weikang Pharmaceutical's stock price was 26.20 yuan per share, with a trading volume of 30.83 million yuan and a turnover rate of 0.81%. The total market capitalization stood at 3.794 billion yuan [1]. - The net inflow of main funds was 248,000 yuan, with significant selling activity amounting to 1.279 million yuan [1].
维康药业跌2.13%，成交额3083.24万元，主力资金净流入24.80万元